De novo and acquired resistance to the anti-tumour drug gefitinib (ZD1839; Iressa), a
specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) has been …

Purpose: The epidermal growth factor receptor (EGFR) may play a relevant role in the
progression, hormone therapy resistance, and prognosis of prostate cancer patients. Also …

In human androgen-independent prostate cancer (PCa), epidermal growth factor receptor
(EGFR) regulates angiogenesis, tumor growth, and progression. In this study, we evaluated …

New drugs and new combinations of drugs have recently shown promising clinical activity in
hormone refractory prostate cancer. We studied the association of gefitinib with trastuzumab …

The epidermal growth factor receptor (EGFR) is highly expressed in many human tumors
and provides a new target for anticancer drug development. EGFR-targeted agents have …

Suppression of invasive phenotype is essential in developing new therapeutic tools to treat
prostate cancer (PC). Evidence indicates that androgen-dependent (AD) prostate cancer …

Background Prostate cancer is a leading cause of male cancer specific mortality. When cure
by radical prostatectomy is not possible the next line of prostate cancer treatment is …

In advanced prostate cancer, cellular changes occur leading to a transition from androgen‐
dependent to androgen‐independent growth. During this transition, proliferation of …

Background Prostate cancer is a common disease in men and at present there is no
effective therapy available due to its recurrence despite androgen deprivation therapy. The …

BACKGROUND The epidermal growth factor receptor (EGFR), a receptor tyrosine kinase, is
over‐expressed in advanced prostate cancer but tyrosine kinase inhibitors are not clinically …